As a result, There is a potential for developing anti-DKD progression therapeutics targeting the RTEC-IgG, which could exert an anti-fibrosis effect through blocking the TGF-β1 signaling pathway. This evidence concerns the gene TGFB1 and diabetic kidney disease.